XBIO - Xenetic Biosciences Inc Stock Price, Fair Value and News

$2.42-0.02 (-0.82%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

XBIO Price Action

Last 7 days

2.1%

Last 30 days

-29.8%

Last 90 days

-42.7%

Trailing 12 Months

-37.0%

XBIO RSI Chart

XBIO Valuation

Market Cap

3.8M

Price/Earnings (Trailing)

-0.95

Price/Sales (Trailing)

1.5

EV/EBITDA

0.02

Price/Free Cashflow

-1.34

XBIO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

XBIO Fundamentals

XBIO Revenue

Revenue (TTM)

2.5M

Rev. Growth (Yr)

-3.44%

Rev. Growth (Qtr)

5.63%

XBIO Earnings

Earnings (TTM)

-4.0M

Earnings Growth (Yr)

9.99%

Earnings Growth (Qtr)

-141.49%

XBIO Profitability

Operating Margin

93.76%

EBT Margin

-670.30%

Return on Equity

-65.93%

Return on Assets

-57.38%

Free Cashflow Yield

-74.88%

XBIO Investor Care

Shares Dilution (1Y)

0.09%

Diluted EPS (TTM)

-2.57

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.4M	2.5M	2.5M	2.5M
2023	1.9M	2.2M	2.4M	2.5M
2022	1.4M	1.5M	1.6M	1.7M
2021	571.4K	746.1K	979.4K	1.2M
2020	4.7M	3.3M	1.9M	436.9K
2019	0	0	0	6.2M
2017	4.1M	5.3M	6.4M	7.6M
2016	0	0	0	3.0M
2015	0	0	0	0
2014	0	0	0	0
2013	0	221.9K	78.4K	692.8K
2012	0	0	126.7K	210.1K

Get all data in R, Python etc through our Historical Stock Data APIs

About Xenetic Biosciences Inc

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

CEO	Mr. Jeffrey F. Eisenberg Esq.
WEBSITE	xeneticbio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	4

Xenetic Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Xenetic Biosciences Inc? What does XBIO stand for in stocks?

XBIO is the stock ticker symbol of Xenetic Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Xenetic Biosciences Inc (XBIO)?

As of Mon Apr 21 2025, market cap of Xenetic Biosciences Inc is 3.76 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XBIO stock?

You can check XBIO's fair value in chart for subscribers.

Is Xenetic Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether XBIO is over valued or under valued. Whether Xenetic Biosciences Inc is cheap or expensive depends on the assumptions which impact Xenetic Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XBIO.

What is Xenetic Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 21 2025, XBIO's PE ratio (Price to Earnings) is -0.95 and Price to Sales (PS) ratio is 1.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XBIO PE ratio will change depending on the future growth rate expectations of investors.